An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.

Key facts

Study ID

NCT01175135

Run by

Pfizer

People needed

259

Starts

2010-10-01

Expected to finish

2011-08-01

Last updated by the study team

2018-05-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of schizophrenia with acute exacerbation of illness
• The current acute exacerbation of schizophrenia must be less than 4 weeks duration prior to the initial evaluation.

You may not qualify if…

• Subjects with evidence or history of clinically significant uncontrolled medical illness
• Subjects with a current diagnosis of schizoaffective disorder, major depression, bipolar disorder, or obsessive compulsive disorder.
• Subjects who meet Diagnostic and Statistical Manual-IV (DSM-IV)defined diagnostic criteria for psychoactive substance dependence (excluding nicotine dependence) within 12 months of screening or DSM-IV defined substance abuse within 3 months prior to screening.

Where it is running

• K & S Professional Research Services, LLC — Little Rock, Arkansas, United States
• Leisure Court Center — Anaheim, California, United States
• Early Phase Investigational Center — Escondido, California, United States
• Synergy Clinical Research Center of Escondido — Escondido, California, United States
• Collaborative Neuroscience Network, Inc. — Garden Grove, California, United States
• Ocean View Psychiatric Health Facility — Long Beach, California, United States
• Long Beach VA Healthcare System — Long Beach, California, United States
• University of California Irvine Medical Center — Orange, California, United States
• California Clinical Trials Medical Group — Paramount, California, United States
• LaPaz Geropsychiatric Center — Paramount, California, United States
• Sharp Mesa Vista Hospital — San Diego, California, United States
• Neuropsychiatric Research Center of Orange County — Santa Ana, California, United States
• Collaborative Neuroscience Network, Inc. — Torrance, California, United States
• Del Amo Hospital — Torrance, California, United States
• Comprehensive Neuroscience, Incorporated — Washington D.C., District of Columbia, United States
• Florida Clinical Research Center, LLC — Bradenton, Florida, United States
• Florida Clinical Research Center, LLC — Maitland, Florida, United States
• Lakeside Behavioral Healthcare — Orlando, Florida, United States
• Atlanta Center for Medical Research — Atlanta, Georgia, United States
• Alexian Brothers Behavioral Health Hospital — Hoffman Estates, Illinois, United States
• Alexian Brothers Center for Psychiatric Research — Hoffman Estates, Illinois, United States
• Chinmay K. Patel, D.O. — Hoffman Estates, Illinois, United States
• Lake Charles Memorial Hospital — Lake Charles, Louisiana, United States
• Lake Charles Clinical Trials — Lake Charles, Louisiana, United States
• CBH Health, LLC — Rockville, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.